Britannia Life Sciences Inc. (BLAB.CN) Comparison with companies in other sectors?

Britannia Life Sciences Inc. has a share price of 162.25M. You can analyze Britannia Life Sciences Inc. (BLAB.CN) competitors across different market sectors through stock heatmaps.

What are BLAB.CN's NET and operating margins?

Britannia Life Sciences Inc. (BLAB.CN) operating margin is around -6.09, and net profit margin is approximately 20.02 as of the latest reports.

In what way does BLAB.CN's earnings per share (EPS) trend reflect its financial momentum?

Britannia Life Sciences Inc. (BLAB.CN) EPS is -0.03 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Britannia Life Sciences Inc. is -2.33, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Britannia Life Sciences Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Britannia Life Sciences Inc. like P/E which is 1.54, P/B which is 1.80, and PEG which is 0.02. Compare them with sector averages to evaluate if the stock is priced fairly.

Britannia Life Sciences Inc.

BLAB.CN•CNQ

Healthcare

Biotechnology

CA$0.07

CA$0.00(0.00%)

Britannia Life Sciences Inc. (BLAB.CN) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.03

P/E Ratio

-2.33

ROE

2.71%

Net Margin

20.02%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$11.36M

Shares OutstandingTotal number of shares issued

$162.25M

Book Value/ShareNet worth per share

$0.04

Revenue/ShareAnnual revenue per share

$0.002

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.03

Net MarginNet income as percentage of revenue

2001.95%

Operating MarginOperating income as percentage of revenue

-609.28%

ROEReturn on shareholders' equity

271.05%

ROAReturn on total assets

63.67%

ROCEReturn on capital employed

-28.27%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.02

Cash/ShareCash and equivalents per share

$0.05

FCF YieldFree cash flow as percentage of market cap

-23.06%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for BLAB.CNFinancial Ratios Analysis details for BLAB.CN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for BLAB.CNSector Benchmarking details for BLAB.CN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Britannia Life Sciences Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Britannia Life Sciences Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Britannia Life Sciences Inc.'s unique business strengths and challenges.

Key Financial Metrics for Britannia Life Sciences Inc.

For Britannia Life Sciences Inc., essential financial indicators include EPS -0.03, PE -2.33, and ROE 2.71. These key ratios reveal insights into Britannia Life Sciences Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Britannia Life Sciences Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Britannia Life Sciences Inc.

Metrics like Net Margin 2001.95% and ROA 63.67% shed light on how well Britannia Life Sciences Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Britannia Life Sciences Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Britannia Life Sciences Inc.

Using ratios such as P/B Ratio 1.80 and PEG Ratio 0.02, investors can assess whether Britannia Life Sciences Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Britannia Life Sciences Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Britannia Life Sciences Inc.

Financial health indicators, such as Debt/Equity Ratio 0.29 and Cash Flow $-0.02, provide a snapshot of Britannia Life Sciences Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Britannia Life Sciences Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Britannia Life Sciences Inc.

Investing in Britannia Life Sciences Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Britannia Life Sciences Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;